A first-in-human, double-blind, placebo-controlled, randomized, dose escalation study of DWP05195, a novel TRPV1 antagonist, in healthy volunteers

OBJECTIVES: DWP05195 is a transient receptor potential vanilloid 1 (TRPV1) antagonist developed for managing pain. The purpose of this study was to evaluate the pharmacodynamics pharmacokinetics, safety, and tolerability of DWP05195 in healthy subjects. This was a first-in-human randomized, double-b...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jieon, Kim, Bo-Hyung, Yu, Kyung-Sang, Kim, Hee Sun, Kim, Ji Duck, Cho, Joo-Youn, Lee, SeungHwan, Gu, Namyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Clinical Trial Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5411174/
https://www.ncbi.nlm.nih.gov/pubmed/28479852
http://dx.doi.org/10.2147/DDDT.S128727

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5411174/
https://www.ncbi.nlm.nih.gov/pubmed/28479852
http://dx.doi.org/10.2147/DDDT.S128727

Ejemplares similares